AmpliPhi Biosciences to Participate in Two Upcoming Conferences
October 11 2017 - 6:50AM
Business Wire
AmpliPhi Biosciences Corporation (NYSE American: APHB), a
clinical-stage biotechnology company focused on the development of
therapies for antibiotic-resistant infections using bacteriophage
technology, today announced that management will present a company
overview at two upcoming investor conferences:
- BIO Investor Forum 2017, San
Francisco, October 18, 2017 at 11:00 a.m.
PDT (2:00 p.m. EDT), company presentation by Paul C. Grint,
M.D., Chief Executive Officer
- Dawson James Securities Small Cap
Growth Conference, Jupiter, Fla., October 19,
2017 at 1:00 p.m. EDT (10:00 a.m. PDT), company
presentation by Steve Martin, Chief Financial Officer
Each presentation will be available on the Events and
Presentations page in the Investor Relations section of AmpliPhi’s
website at www.ampliphibio.com.
About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation is a clinical-stage
biotechnology company focused on treating antibiotic-resistant
infections using its proprietary bacteriophage-based technology.
AmpliPhi’s lead product candidates target
multidrug-resistant Staphylococcus aureus and Pseudomonas
aeruginosa, which are included on the WHO’s 2017 Priority
Pathogens List. Phage therapeutics are uniquely positioned to
address the threat of antibiotic-resistance as they can be
precisely targeted to kill select bacteria, have a differentiated
mechanism of action, can penetrate and disrupt biofilms (a common
bacterial defense mechanism against antibiotics), are potentially
synergistic with antibiotics and have been shown to restore
antibiotic sensitivity to drug-resistant bacteria. For more
information visit www.ampliphibio.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171011005217/en/
At the Company:AmpliPhi
BiosciencesMatthew Dansey,
858-800-4869md@ampliphibio.comorInvestor
Relations:Westwicke PartnersRobert H. Uhl,
858-356-5932robert.uhl@westwicke.comorMedia:Russo Partners, LLCDavid Schull or
Maggie Beller,
212-845-4271David.Schull@RussoPartnersLLC.comMaggie.Beller@RussoPartnersLLC.com
Armata Pharmaceuticals (AMEX:ARMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Armata Pharmaceuticals (AMEX:ARMP)
Historical Stock Chart
From Apr 2023 to Apr 2024